Related Experiment Video
Updated: Jan 27, 2026

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
Published on: November 28, 2016
Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication
Yusuke Tomoi1, Kyohei Yamaji1, Yoshimitsu Soga1
11 Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Insights
Elevated low-density lipoprotein cholesterol (LDL-C) levels after endovascular therapy (EVT) for peripheral artery disease (PAD) increase cardiovascular death risk. Intensive LDL-C lowering may improve outcomes, especially for patients on statin therapy.
Area of Science:
- Cardiovascular Medicine
- Vascular Surgery
- Interventional Cardiology
Background:
- Peripheral artery disease (PAD) affects lower limbs and increases cardiovascular risk.
- Endovascular therapy (EVT) is a common treatment for symptomatic PAD.
- Optimizing lipid management post-EVT is crucial for long-term outcomes.
Purpose of the Study:
- To examine the association between low-density lipoprotein cholesterol (LDL-C) levels and 5-year cardiovascular death rates after EVT in PAD patients.
- To investigate this association based on statin therapy status at discharge.
Main Methods:
- Analysis of 935 patients with lower limb PAD who underwent EVT.
- Correlation of LDL-C levels (measured 3-6 months post-EVT) with 5-year cardiovascular death (CVD).
- Multivariate analysis to identify independent predictors of CVD, with a focus on LDL-C ≥100 mg/dL.
Main Results:
- CVD occurred in 8.9% of patients over a median follow-up of 30.7 months.
- Patients with LDL-C ≥100 mg/dL had a significantly higher 5-year CVD incidence (23.5% vs. 13.5%, p=0.03).
- LDL-C ≥100 mg/dL was an independent predictor of CVD (adjusted HR 1.60, p=0.049), particularly in patients on statin therapy.
Conclusions:
- Higher LDL-C levels (≥100 mg/dL) 3-6 months post-EVT for PAD are independently linked to increased CVD risk.
- This association is more pronounced in patients receiving statin therapy.
- Intensified LDL-C-lowering strategies may be necessary to enhance clinical outcomes in this patient population.
Purpose:
To investigate the association between low-density lipoprotein cholesterol (LDL-C) levels and the 5-year cardiovascular death rate after endovascular therapy (EVT) in patients with lower limb peripheral artery disease (PAD) according to statin therapy status.
Methods:
From January 2010 to March 2016, 1324 PAD patients (1670 limbs) with claudication (Rutherford category 1-3) underwent EVT. After excluding 389 patients owing to death or missing data, 935 (70.6%) patients (mean age 72.1±8.7 years; 708 men) were included in the analysis. Statin therapy was prescribed to 509 (54.4%) patients at discharge. LDL-C levels at 3 to 6 months after EVT were correlated with the incidence of cardiovascular death (CVD; procedure-related and proximate cardiac, noncoronary vascular, or unknown causes) at 5 years. A stratifying factor of 100 mg/dL was based on the median LDL-C value (94 mg/dL) in the cohort. Predictors of CVD were sought in multivariate analysis; results are presented as the hazard ratio (HR) and 95% confidence interval (CI).
Results:
Over a median follow-up of 30.7 months (interquartile range 13.7, 47.6), CVD occurred in 83 (8.9%) patients. The incidence of CVD at 5 years was significantly higher in patients with LDL-C ≥100 mg/dL at 3 to 6 months than in those with LDL-C <100 mg/dL (23.5% vs 13.5%, p=0.03). In addition, LDL-C ≥100 mg/dL at 3 to 6 months was associated with a higher incidence of CVD (25.2% vs 10.9%, p=0.02) in 509 (54.4%) patients with statin therapy at discharge. In the multivariate model, LDL-C ≥100 mg/dL at 3 to 6 months after EVT was an independent predictor of CVD (adjusted HR 1.60, 95% CI 1.001 to 2.59, p=0.049).
Conclusion:
LDL-C ≥100 mg/dL at 3 to 6 months after the EVT for symptomatic lower limb PAD was independently associated with a higher risk of CVD, particularly in patients on statin therapy at discharge. This observation suggests that intensive LDL-C-lowering therapy may be needed to improve clinical outcomes.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Density
High-Level and Low-Level Awareness
Leveling Effect
Gene Therapy
Current Density

